Aims: The PREVIEW lifestyle intervention study (ClinicalTrials.gov Identifier: NCT01777893) is, to date, the largest, multinational study concerning prevention of type-2 diabetes. We hypothesized that the initial, fixed low-energy diet (LED) would induce different metabolic outcomes in men vs women.
| INTRODUCTION
Type 2 diabetes mellitus is one of the fastest growing chronic diseases worldwide. 1 We are aware of the major risk factors, including overweight or obesity, and know that achieving weight loss "prevents diabetes" in the sense that onset of new cases is delayed. The most recent paper exploring the dose-response effect of weight loss shows that more than 4.3% weight loss is needed to prevent diabetes, for 3 years, in Japanese men. 2 The PREVIEW intervention study (PREVention of diabetes through lifestyle Intervention and population studies in Europe and around the World; www.previewstudy.com) is, to date, the largest, multinational study that aims to prevent type 2 diabetes in overweight individuals with pre-diabetes. Diet and physical activity are utilized, with changes being reinforced by behavior modification techniques. 3 The study is an ongoing 3-year multicentre, 2-by-2 factorial, randomized controlled trial, in which eligible adult participants initially followed an 8-week low-energy diet (LED). The aim was to induce weight loss of at least 8%, in order to qualify for inclusion in the randomized intervention where the focus is on longterm weight loss maintenance. 4 The majority of individuals who use weight loss programmes, including bariatric surgery, are women. 5, 6 Investigating whether outcomes differ between men and women is import in developing gender-specific treatment programmes, if required. [6] [7] [8] [9] [10] [11] [12] Differences in outcome after weight loss have been reported previously, with men commonly losing more body weight and fat than women. 13 This difference is mainly explained by the concept of the LED, in which a fixed daily energy intake is provided to both genders, despite men and women having significantly different energy requirements because men characteristically have a greater body mass. Notably, however, men may mobilize more intra-abdominal fat than women during weight loss, whereas women may lose more subcutaneous fat. 14, 15 The greater reduction in intra-abdominal fat in men is accompanied by a more pronounced improvement in metabolic risk profile. Therefore, greater improvement in terms of risk factors in men is not only related to a greater negative energy balance, but also to a gender-specific effect. 16, 17 Of interest are the differences in glycaemia between overweight men and women. The prevalence of pre-diabetes has been reported to be significantly higher in men than in women. 18 Impaired fasting glucose (IFG), which is indicative of hepatic insulin resistance (IR), is also more common in men, typically 1.5-3 times higher. 19 Conversely, the prevalence of impaired glucose tolerance (IGT), which is indicative of skeletal muscle IR, has been reported to be higher in women than in men in almost all age groups. 16 In this study, we aimed to compare the effects of an 8-week LEDinduced weight loss on metabolic outcomes in a large group of men and women. The study included data from adult participants aged 25-70 years who were enrolled in the PREVIEW diabetes prevention study.
| MATERIALS AND METHODS
Adult participants were recruited to the PREVIEW study between 
| Interventions
The PREVIEW study comprises 2 intervention phases. Phase 1 is an 8-week, weight-loss phase using a formula LED (3.4 MJ/d) intended to induce weight loss of ≥8% to qualify for the next phase. Phase 2 is an ongoing 148-week randomized lifestyle intervention that focuses on diet, physical activity and behaviour modification for maintenance of weight loss. The LED was implemented by using a range of formula products of the Cambridge Weight Plan (Northants, UK). All intervention sites used the standard assortment from the Cambridge Weight Plan available in the UK to ensure that the nutritional content of sachets was identical. The sachets, which included soups, shakes and porridges, were provided to participants without charge. Participants were instructed to consume 4 sachets (4 × 40 g) per day. Of these, 3 sachets were to be dissolved in milk (3 × 250 mL low fat milk, total 750 mL/d) and 1 sachet in 250 mL of water. The fat content of the milk was ≤0.5 g/100 mL and the energy content ≤170 kJ and liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Blood samples were drawn from the antecubital vein. Serum and whole blood samples were initially stored at −80 C at the individual intervention sites, after which they were transported to a laboratory and bone mineral density (BMD).
Systolic (SBP) and diastolic (DBP) blood pressure and heart rate were measured using a validated automatic device on the right arm after 5-10 minutes in a resting position. Measurements were performed 3 times with a 1-minute rest between each recording and the mean value was recorded. Pulse pressure was calculated using the formula SBP minus DBP. Mean arterial pressure (MAP) was calculated using the formula 0.42 × SBP + 0.58 × DBP. 26 Metabolic syndrome (MS) was evaluated using an MS Z-score, which is a continuous score of the 5 MS variables, as reported previously. 27 Gender-specific Z-scores were used to account for variations in criterion between men and women. The equations used were: At all visits to the intervention sites, participants were asked whether they had experienced adverse events (AEs). Any reported AE was noted on a related form that captured onset, end, intensity, causality, action taken and outcome of the AE.
| Statistical methods
Descriptive characteristics at CID1 and CID2 are summarized as mean AE SD. Differences between men and women were analysed using a linear mixed model, including intervention site as random effect. The estimate of mean difference at baseline is presented as mean AE SEM.
All analyses were carried out as complete-case analyses, that is, data from all participants who attended both the baseline visit (CID1) and the visit at Week 8 (CID2), independent of the amount of weight loss.
Count data, such as number of participants who dropped out or achieved a successful weight loss were analysed for group differences by simple 2 × 2 contingency tables and Chi-square. For continuous outcomes, the mean gender difference was estimated using ANCOVA-type linear mixed models, adjusting for fixed effects of and most were of mixed origin. On average, the age of included individuals was 51.6 AE 11.6 years, body weight was 100.1 AE 21.4 kg, BMI was 35.4 AE 6.6 kg/m 2, HOMA-IR was 3.75 AE 2.43 and FPG was 6.2 AE 0.7 mmol/L. Baseline characteristics are shown in Table 1 .
Changes after the LED are shown in A separate analysis of changes in anthropometry, HOMA-IR and blood markers in female participants in different age groups is shown in Appendix S4. The younger age group (<45.9 years) experienced statistically different changes in HOMA-IR, HbA1c, insulin, HDL cholesterol, ALT, thigh circumference, BMC, BMD and heart rate compared to the two older age groups (46-54 years and > 55 years). Between the older age groups, changes in HbA1c, ALT, thigh circumference and BMD were statistically significantly different after the LED weight loss.
During the LED weight loss period, 961 AEs were reported across all sites. Of these, 10 events were reported as serious adverse events (SAEs). However, all SAEs were evaluated as unlikely to be related, or unrelated, to the study intervention and the LED weight loss. Women reported significantly more adverse events than men (Table 3 ). The main AEs were constipation, cold/influenza, muscular weakness and pain.
| DISCUSSION
In this worldwide intervention study, participants lost an average of 11% body weight and showed significant improvements in insulin resistance (change in HOMA-IR, −1.4; P < 0.001) after an 8-week
LED. There were differences in other metabolic outcomes according to gender; men appeared to benefit more than women. Men lost significantly more body weight than women, and had larger reductions in metabolic syndrome Z-score, C-peptide, FM and heart rate, even after adjusting for differences in weight loss (%). In contrast, women had larger reductions in HDL cholesterol, hip circumference, BMC, FFM and pulse pressure than men, again after adjustment for differences in weight loss (%). As declines in HDL cholesterol, BMC and lean mass are generally not supportive of long-term health, it is of general interest to determine whether rapid weight loss with a LED compromises the health of some women. Therefore, it is of importance to investigate whether the long-term effects of rapid weight loss are indeed more beneficial for men than for women with regard to prevention of both type-2 diabetes and cardiovascular disease. Previous studies have reported that differences in metabolic outcome according to gender occur because men mobilize more intraabdominal fat than women during weight loss, and that this is accompanied by a more pronounced improvement in the metabolic risk profile. 12, 14, 15 In the present study, we found important differences when comparing outcomes between women and men, both before and after adjusting for differences in weight loss (%). This suggests intrinsic differences in how men and women adapt to dietary energy deficits.
Following LED weight loss, the loss of FFM was, on average, 25% of the total weight loss. Changes in FFM of this magnitude are considered normal during LED weight loss. 28 31 It would be interesting to investigate differences between men and women in compliance with and adaptation to the LED phase as it may help explain the differences found in this analysis.
Physical activity (PA) and exercise training are associated with numerous health benefits. 33 In the PREVIEW study, we did not measure the level of physical activity during or immediately after the LED weight-loss phase. Differences in physical activity level between participants could have impacted some results presented in this paper;
however, the strict inclusion criterion (absence of high PA) led to a narrower between-person variance in PA, which decreased the likelihood that one could find an association between PA, weight loss and the related outcomes. The included participants were, more or less, physically inactive and no guidance concerning PA was given during the LED phase. Although we do not have direct evidence, it is unlikely that any major changes in PA occurred during the LED phase.
In the PREVIEW study, different equipment was used to measure body composition at the different intervention sites (Appendix S3);
however, the same equipment was always used to measure a given For difference between men and women the estimate is given as mean difference AE SEM adjusted for site; *P < 0.05, **P < 0.01, ***P < 0.001.
b
The formula to calculate the HOMA-IR was: fasting insulin(mU/L)
The metabolic syndrome was calculated as a Z score. The formula used to calculate MAP was 0.42 x SBP + 0.58 x DBP. 26 participant. There are many body composition methods available to estimate different body compartments. 34, 35 The more practical and acceptable methods that are frequently used to estimate body composition include Dual-energy X-ray absorptiometry (DXA) and bioimpedance analysis (BIA), which were primarily used in the current study. The validity of DXA and BIA has been debated previously; their accuracy can vary according to age, adiposity, etc. 34, 36 In this study, using different equipment at the various sites may have introduced some variability in the data. However, as the same equipment was always used for a given participant, and as adjustments were made for the site in the analyses, we believe that we have limited the bias to the greatest extent possible while we acknowledge that not using the same equipment across all sites is a weakness of the trial.
Additionally, 87.6% of the study participants described themselves as Caucasian and the remaining participants were Polynesians Asian, Hispanic, Black or of mixed origin. Therefore, the ethnic diversity of PREVIEW participants does not allow generalization of the results to all ethnic groups but primarily to Caucasians. Drop-out rates during the LED were generally low but varied across centres, from 2.5% to 14.4%. The lower drop-out rate in men might be explained by the greater, early success experienced by men using the LED. There can be many reasons for the difference in dropout rates across sites. At some sites, participants were not as familiar with using formula LEDs for weight loss as those at other sites; thus, cultural and social challenges varied. Differences in compliance and efficacy of the LED in different settings have also been reported in an earlier large-scale study. 37 As outlined in this discussion, many aspects of the study could have contributed to the gender-specific effects that we found.
Regional fat distribution is indeed different between men and women and, as described earlier, men may mobilize more intra-abdominal fat than women, whereas women may lose more subcutaneous fat during weight loss. 14, 15 However, our aim with these analyses was not to attempt to disentangle the various contributors to gender-specific effects, that is, gender-specific hormones, behaviour and compliance during the LED. Our aim was to assess gender-specific effects as a whole and future analysis of our data could explore what constitutes these gender-specific effects.
In the separate analysis investigating differences between age groups within the female population, we found several statistically significant findings. Whether these findings are clinically important or simply statistically significant findings is difficult to interpret.
Generally, weight loss is known to be associated with improvements in liver transaminases once weight stability has been achieved. 38 However, our current study is consistent with the existing literature in showing that transient mild increases in liver enzymes can be observed in some individuals immediately after an LED period. 39 Increments were significantly larger in women than in men. It has been reported in previous studies that values return to normal within a few weeks. 24 The consequences of the changes are believed to be benign if the enzyme elevation is transient. 39 An important strength of our study is the large sample size and the wide age span, in all sites in Europe, Australia and New Zealand. In addition, criteria for identifying pre-diabetes were consistent from site to site as ADA criteria (IFG, 5.6-6.9 mmol/L) 22, 40 were used. The range for identifying IFG according to the World Health Organization is narrower (6.1-6.9 mmol/L). 40 However, in the present study, following The results presented in this analysis provide data only on shortterm changes. Indeed, maintaining weight loss and the accompanying improvements is challenging. 42, 43 Whether PREVIEW participants are able to maintain the weight loss and achieved metabolic responses, and whether differences between genders persist in the long term will be apparent once the trial is completed. However, the 8-week LED in individuals with pre-diabetes did result in the initial 10% weight loss needed to achieve major metabolic improvement in the first phase of a diabetes prevention programme.
In conclusion, an 8-week LED was accompanied by significant improvements in anthropometry, blood pressure and metabolic profile in overweight women and men with pre-diabetes. While HOMA-IR improved in all participants, regardless of gender, men lost significantly more body weight than women and had larger reductions in metabolic syndrome Z-score, C-peptide and FM, even after adjusting for differences in weight loss (%). In contrast, women had larger reductions in HDL cholesterol, FFM and BMC that could be considered undesirable. These findings are clinically important and suggest gender-specific differences between men and women after weight loss. It is of importance to investigate whether the greater reduction in FFM, BMC, hip circumference and HDL cholesterol in women after rapid weight loss is indeed beneficial or, rather, might compromise weight loss maintenance and future optimal/good cardiovascular health.
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